International Journal of Particle Therapy (Jul 2021)

Radiation Necrosis with Proton Therapy in a Patient with Aarskog-Scott Syndrome and Medulloblastoma

  • Vidya Puthenpura, MD,
  • Nicholas J. DeNunzio, MD, PhD,
  • Xue Zeng, PhD,
  • Drosoula Giantsoudi, PhD,
  • Mariam Aboian, MD, PhD,
  • David Ebb, MD,
  • Kristopher T. Kahle, MD, PhD,
  • Torunn I. Yock, MD,
  • Asher M. Marks, MD

DOI
https://doi.org/10.14338/IJPT-21-00013.1
Journal volume & issue
Vol. 8, no. 3
pp. 58 – 65

Abstract

Read online

Purpose: Medulloblastoma is known to be associated with multiple cancer-predisposition syndromes. In this article, we explore a possible association among a patient's Aarskog-Scott syndrome, development of medulloblastoma, and subsequent brainstem radiation necrosis. Case Presentation: A 5-year-old male with Aarskog-Scott syndrome initially presented to his pediatrician with morning emesis, gait instability, and truncal weakness. He was ultimately found to have a posterior fossa tumor with pathology consistent with group 3 medulloblastoma. After receiving a gross total resection and standard proton beam radiation therapy with concurrent vincristine, he was noted to develop brainstem radiation necrosis, for which he underwent therapy with high-dose dexamethasone, bevacizumab, and hyperbaric oxygen therapy with radiographic improvement and clinical stabilization. Conclusion: Based on several possible pathologic correlates in the FDG1 pathway, there exists a potential association between this patient's Aarskog-Scott syndrome and medulloblastoma, which needs to be investigated further. In patients with underlying, rare genetic syndromes, further caution should be taken when evaluating chemotherapy and radiation dosimetry planning.

Keywords